Loading stock data…
ALNY
$296.11-13.38 (-4.32%)
Market ClosedLast close May 1
Alnylam Pharmaceuticals, Inc.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Alnylam Pharmaceuticals, Inc. in the Healthcare sector is trading at $296.11. The stock is currently 40% below its 52-week high of $495.55, remaining 24.6% below its 200-day moving average. Technical signals show oversold RSI of 28 and bearish MACD signal, explaining why ALNY maintains its current current market pressure. The Whystock Score of 60/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Oversold momentum (RSI 28) — potential for technical mean-reversion
Long-term trend bearish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$296.11
Potential Downside
92.7%
Whystock Fair Value$21.70
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus25 analysts
Buy
Mean target$449.48+51.8%
Range$310.00 – $566.00
Fundamentals
Alnylam Pharmaceuticals, Inc. discovers, develops, manufactures, and commercializes therapeutics based on ribonucleic acid interference in the United States, Europe, and internationally. The company offers ONPATTRO for hereditary transthyretin-mediat...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$41.87B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
135.25
Beta
Defensive asset. Lower volatility than the S&P 500.
0.38
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-40.43%
Volume
Today's trading volume
1.12M
Recent News
Extreme Networks And 2 Additional Stocks Estimated To Be Trading Below Their Fair Value
In the last week, the United States market has stayed flat, yet it is up 29% over the past year with earnings forecasted to grow by 16% annually. In such a climate, identifying stocks that are potentially undervalued can present opportunities for investors looking to capitalize on discrepancies between stock prices and their intrinsic values.
Alnylam Q1 Earnings Beat Estimates, Amvuttra Sales Drive Y/Y Growth
ALNY beats Q1 earnings and revenue estimates as Amvuttra sales surge 187%, driving 96% revenue growth and offsetting declines in collaborator revenue and Onpattro sales.
Discover 3 Stocks That Might Be Trading Below Estimated Value
In the last week, the United States market has stayed flat, although it is up 29% over the past year with earnings forecasted to grow by 16% annually. In such a climate, identifying stocks that might be trading below their estimated value can offer potential opportunities for investors seeking to capitalize on future growth.
Alnylam Pharmaceuticals, Inc. Q1 2026 Earnings Call Summary
Moby summary of Alnylam Pharmaceuticals, Inc.'s Q1 2026 earnings call
Alnylam Surges After Its Pfizer-Rivaling Blockbuster Jumps Nearly 200%
Alnylam stock popped Thursday on a solid first-quarter beat for its Pfizer-rivaling heart disease drug, Amvuttra.